G1SK34.SA
Strong BuyUnloved QualityFLAGGSK plc · Healthcare · United Kingdom · $101.2B · Avg Vol: $768.387/d
Unloved Quality: Strong and cheap, but the market has not turned yet. Patience required.
Insufficient evidence for a screen-pass. GSK plc: fails the quant gate on momentum (Q73/V73/M47; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
ABOUT GSK PLC
Read
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
FINANCIAL SUMMARY (BRL)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 201.9B | 208.9B | 216.1B | 225.0B | 3.7% | 228.1B | 233.8B | 244.4B | 4.2% |
| EPS (BRL) | 4.18 | 1.36 | 0.71 | 1.56 | -28.1% | 3.25 | — | — | — |
| Shares | 10.0B | 10.0B | 10.0B | 10.0B | 0.0% | 10.0B | — | — | — |
| Debt | 144.5B | 124.1B | 117.0B | 122.0B | -5.5% | 125.7B | — | — | — |
| Equity | 73.0B | 91.9B | 94.1B | 112.8B | 15.6% | — | — | — | — |
| Op CF | 51.0B | 46.6B | 45.1B | 53.3B | 1.5% | 57.2B | — | — | — |
| Inv CF | -60.4B | -11.0B | -8.5B | -29.2B | — | — | — | — | — |
| Fin CF | 5.7B | -38.8B | -32.5B | -25.4B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of G1SK34.SA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| G1SK34.SA | GSK plc(you) | $101.2B | 92 | Strong Buy |
| SAN.PA | Sanofi | $107.2B | 93 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $136.0B | 98 | Strong Buy |
| PFE | Pfizer Inc. | $159.4B | 87 | Strong Buy |
| N1VO34.SA | Novo Nordisk A/S | $201.0B | 93 | Strong Buy |
| 4578.T | Otsuka Holdings Co., Ltd. | $40.0B | 92 | Strong Buy |
| AMGN | Amgen Inc. | $233.8B | 88 | Strong Buy |
| BAYN.DE | Bayer Aktiengesellschaft | $55.4B | 79 | Buy |
| NOVN.SW | Novartis AG | $290.6B | 86 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $180.6B | 75 | Buy |
Peer medians: ROE 2.7% · P/E 23.6x · Gross margin 52.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.